ReviewBritish journal of clinical pharmacology2006
Monitoring for adverse drug reactions.
Review in British journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic review.Drug safety · 2011Pooled it
- Prescribing Errors in Iraqi Intensive and Cardiac Care Units: A Qualitative Investigations of Pharmacists' Perceptions, Determining Factors, Outcomes and Management Strategies.Journal of multidisciplinary healthcare · 2026Article
- Physicians' Attitudes and Practices Regarding Drug Allergy Management: A Cross-Sectional Study.Cureus · 2025Article
- Clinical Implications of Herbal Supplements in Conventional Medical Practice: A US Perspective.Cureus · 2022Review
- Poisonous Plants of the Indian Himalaya: An Overview.Metabolites · 2022Review
- Reducing Medication Harms: Thoughts and Strategies.Global journal on quality and safety in healthcare · 2021Article
- Critical Analysis of Non-Thermal Plasma-Driven Modulation of Immune Cells from Clinical Perspective.International journal of molecular sciences · 2020Review
- The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia.British journal of clinical pharmacology · 2017Article
- Adverse drug reactions.Clinical medicine (London, England) · 2016Review
- Beyond the prescription: medication monitoring and adverse drug events in older adults.Journal of the American Geriatrics Society · 2011Article
- Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care.British journal of clinical pharmacology · 2010Article
- A strategy for regulatory action when new adverse effects of a licensed product emerge.Drug safety · 2009Review
- On pharmaceutical risk minimization.Drug safety · 2008Article
- Monitoring for harms of therapy.British journal of clinical pharmacology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monitoring describes the prospective supervision, observation, and testing of an ongoing process. The result of monitoring provides reassurance that the goal has been or will be achieved, or suggests changes that will allow it to be achieved. In therapeutics, most thought has been given to Therapeutic Drug Monitoring, that is, monitoring of drug concentrations to achieve benefit or avoid harm, or both. Patients and their clinicians can also monitor the progress of a disease, and adjust treatment accordingly, for example, to achieve optimum glycaemic control. Very little consideration has been given to the development of effective schemes for monitoring for the occurrence of adverse effects, such as biochemical or haematological disturbance. Significant harm may go undetected in controlled clinical trials. Even where harm is detected, published details of trials are usually insufficient to allow a practical monitoring scheme to be introduced. The result is that information available to prescribers, such as the Summary of Product Characteristics, frequently provides advice that is incomplete or impossible to follow. We discuss here the elements of logical schemes for monitoring for adverse drug reactions, and the possible contributions that computerized decision support can make. We should require evidence that if a monitoring scheme is proposed, it can be put into practice, will prove effective, and is affordable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.